Diseases of Pulmonary Vasculature
Featured Article
Perioperative Risk Assessment in a Patient With COPD
A 64-year-old man with chronic obstructive pulmonary disease, diabetes, chronic kidney disease, and morbid obesity seeks preoperative approval for femoral popliteal bypass surgery.
Latest Features
Lung Transplantation in Pulmonary Arterial Hypertension: An Overview
Evaluating diagnosis and treatment options for pulmonary arterial hypertension.
Worsening Shortness of Breath in a 40-Year-Old Woman: A Case Study
A 40-year-old woman presents with worsening shortness of breath after being treated with long-acting nifedipine for 2 years.
Pulmonary Arterial Hypertension: Mechanisms of Exercise Intolerance
Exercise intolerance is a hallmark symptom of pulmonary arterial hypertension.
Diagnostic Value of Bronchoalveolar Lavage in Idiopathic Pulmonary Fibrosis
The diagnostic value of bronchoalveolar lavage in idiopathic pulmonary fibrosis is evaluated.
Chronic Thromboembolic PH Diagnosis and Management Update: Expert Q&A
Development of CTEPH is associated with traditional thrombotic risk factors, including thrombophilias and inflammatory processes.
Pulmonary Arterial Hypertension: Treatment Tailored by Race and Ethnicity
Future clinical trials on pulmonary arterial hypertension should include patients from diverse racial and ethnic backgrounds.
Bronchopulmonary Dysplasia and Pulmonary Hypertension in Preterm Neonates
The most common chronic respiratory morbidity affecting preterm neonates is bronchopulmonary dysplasia.
Pulmonary Complications After Noncardiac Surgery Ameliorated By Pulmonary Rehab
The risk of perioperative complications is increased by many factors in patients undergoing thoracic surgery.
Pulmonary Arterial Hypertension and Genetics: Interview With the Experts
James E. Loyd, MD, and Wendy Chung, MD, PhD, offer insight into the role of genetics in pulmonary arterial hypertension.
Latest News
Benefits of Targeted Pharmacologic Therapy in PAH and Distal CTEPH
In patients with pulmonary arterial hypertension or distal chronic thromboembolic pulmonary hypertension, targeted pharmacologic treatment was associated with an increase in achieved therapeutic goals.
Pulmonary Arterial Hypertension Outcomes With Atrial Arrhythmia
Increased right atrial and pulmonary wedge pressures and increased thyroid disease prevalence were associated with atrial arrhythmia development in idiopathic or systemic sclerosis-related pulmonary arterial hypertension.
Oral Treprostinil Dosing Characteristics in Pulmonary Arterial Hypertension
Prescribers tend to favor a frequency of 3 times per day for oral treprostinil dosing in patients with pulmonary arterial hypertension.
Pulmonary Hypertension Outcomes Predicted by NT-pro BNP
N-terminal-pro brain natriuretic peptide may be a useful biomarker for both mortality and respiratory exacerbations in pediatric patients with pulmonary hypertension.
Pulmonary Hypertension Mortality Following Cardiac Catheterization
Patients with pulmonary hypertension have a high risk for adverse events during and following cardiac catheterization, but high case volume may help ameliorate this risk.
PDE-5 Inhibitor Prescribing Trends Do Not Meet Pulmonary Hypertension Guidelines
Nearly two-thirds of phosphodiesterase-5 inhibitor prescriptions are inconsistent with pulmonary hypertension guidelines.
Pulmonary Arterial Hypertension Identified Via Claims-Based Algorithm
Patients with pulmonary arterial hypertension may be better identified with the use of a claims-based algorithm that includes ICD-9-CM codes, electronic medical records, and more.
Right Atrium Enlargement Predicts Supraventricular Arrhythmia Risk in PAH
Right atrium enlargement may predict the risk for supraventricular arrhythmias in patients with pulmonary arterial hypertension.
Long-Term Prognosis in Women vs Men With Pulmonary Arterial Hypertension
Women with pulmonary arterial hypertension may have better long-term prognoses compared with men, potentially because of improvements in right ventricular function.
Pulmonary Embolism Rule-Out Criteria Can Identify Thromboembolic Events
A 3-month risk for a thromboembolic event was assessed using a pulmonary embolism rule-out criteria strategy and compared with a conventional strategy in patients with a low clinical probability of pulmonary embolism.
Pulmonary Embolism With Low Mortality Risk Treated in Outpatient Setting
Acute pulmonary embolism may be managed in an outpatient setting when the patient has a low risk for mortality.
Idiopathic PAH-Associated Hypoxemia Linked to Poor Survival, Increased Comorbidities
Hypoxemia is associated with reduced survival in patients with idiopathic or heritable pulmonary arterial hypertension.
Peak Circulatory Power Is a Potent Predictive Tool in Idiopathic PAH
Peak circulatory may provide reliable prognostic information in patients with idiopathic pulmonary arterial hypertension.
6MWT Clinically Relevant and Appropriate Prognostic Tool for PAH
The 6MWT is a clinically relevant and appropriate target for patients with pulmonary arterial hypertension.
Pulmonary Embolism Risk Prediction in Postpartum Women
Certain risk scores may not be reliable for predicting the presence of a pulmonary embolism in pregnant or postpartum women.
Pulmonary Hypertension Treatments Targeting NO Pathway Compared for Safety
Several drugs may demonstrate different safety profiles and side effects that warrant a change in treatment for individuals with pulmonary hypertension.
Two 6-Minute Walk Tests Recommended for Suspected Pulmonary Hypertension
To minimize the "learning effect" and improve accuracy, patients with suspected pulmonary hypertension should undergo two 6-minute walk tests.
Pulmonary Arterial Hypertension: Biomarker May Predict 5-Year Survival
Monitoring the plasma BNP level in individuals with pulmonary arterial hypertension may aid clinicians in therapeutic decision-making and overall prediction of 5-year survival rate.
Global Pulmonary Vascular Remodeling and Pulmonary Hypertension in Heart Failure
Researchers discovered an association between global pulmonary vascular remodeling and pulmonary hypertension in patients with heart failure.
Assessment of Ambrisentan in Pulmonary Arterial Hypertension
In a postmarketing surveillance study, ambrisentan demonstrated tolerability and potential effectiveness for pulmonary arterial hypertension treatment.
The Cardiology Advisor Articles
- The Mounting Evidence Against Electronic Cigarette Use
- Entresto Significantly Improves Physical, Social Activity in Heart Failure Patients
- Oxygen Therapy in Acute MI Not Associated With Clinical Benefit
- Nonpsychotic Cannabinoids in Hypertension: Benefits and Harms
- ACC and AHA Release 2018 Quality Measures for Cardiac Rehabilitation